Christie Digital Christie Digital
Christie CounterAct UVC disinfection light fixture
Overview Videos Specs Downloads Images

The disinfection technology we need right now—and tomorrow

Christie CounterAct commercial UVC disinfection fixtures contain patented Care222® technology that emits filtered far-UVC 222nm light while meeting established safety guidelines, designed to neutralize pathogens with people present. Care222 is also the world’s first UVC technology with a proprietary optical filter that blocks potentially harmful longer UVC wavelengths from being emitted.

An added layer of defense

The far-UVC 222nm light that Care222 technology emits provides an added layer of defense against pathogens like the SARS-CoV-2 coronavirus that causes COVID-19. CounterAct CA-20 fixtures are designed for high-ceiling applications, from corporate, government, and education, to transit hubs, cinemas, museums, theme parks and indoor locations, and beyond.

Purpose-built with your needs in mind

  • Configurable, automated operation within the current limits of ACGIH and IEC occupational and environmental health guidelines, which can be reconfigured if these guidelines evolve over time
  • Programmable to operate on a specific schedule according to your use case
  • As easy to install as traditional commercial lighting fixtures, with automated control via an app
  • Easy-to-service for straightforward lamp changes
  • Instant on/off at full output power, and frequent on/off cycles don’t affect lamp life
  • Available in black or white to fit existing color schemes
  • Designed for high-ceiling applications
  • Flexible leasing options are available

Design services

We can work with you to determine how many CounterAct fixtures you need to provide effective coverage of your indoor space. We offer consulting and installation services through our Professional Services group to help with a deployment strategy to add a layer of defense against pathogens in shared indoor spaces.

All references to “disinfect”, “disinfecting” and “disinfection” refer generally to the reduction of pathogenic bioburden and are not intended to refer to any specific definition as may be used by any governmental or regulatory authority including the U.S. Food and Drug Administration and the U.S. Environmental Protection Agency. Christie CounterAct products with patented Care222 technology are not medical devices and are not to be used as or for medical devices. The pathogen-reducing efficacy of Christie CounterAct products and their use in occupied spaces is dependent on many site-specific factors as well as proper installation and operation within specifications and in accordance with American Conference of Governmental Institutional Hygienist (ACGIH) guidelines. Professional installation is recommended for Christie CounterAct products. “Christie” is a trademark of Christie Digital Systems USA, Inc., registered in the United States of America and other countries. This product uses Care222® technology developed by Ushio Inc. Care222® is a trademark or registered trademark of Ushio Inc. and Ushio America, Inc.


Let's return to the places we love - Christie CounterAct products with patented Care222 technology


Let's return to the places we love

Ushio Care222® Filtered Far UV-C Excimer


Ushio Care222 far-UVC technology


Power supply

  • 220-240(CE) / 100-277V (UL)

Power consumption

  • 45W (AC version)

Rated current

  • 230mA (CE) / 450mA (UL) max


  • 50/60Hz

Emission wavelength

  • 222nm

Emission angle

  • 60°

*Tablet is not included. Android OS only. Recommended tablets for operation: Samsung Galaxy Tab A 8" or 10.1"